The MNA mutational landscape. Samples from 19 MNA patients were assessed for histopathology and cellularity (a), analyzed for somatic mutations (Additional file 3: Tables S4 and S11) (b) or copy number aberrations (Additionalfile 3: Tables S7-S9) (c) as identified by exome sequencing using the discovery group (10 MCP samples - left side) or as validated by digital PCR and deep sequencing (19 samples - right side). (d) The levels of pErk, pAkt, and phosphorylated PKA substrates were measured by immunohistochemistry and determined to be positive based on signal strength and fraction of positive cells (Methods). (*) Only expected codons were investigated in the validation group. Low cellularity may impact the sensitivity of the validation.